<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec><h3>Background</h3>
<p>The family of calcium-activated chloride channels, TMEM16, plays a significant role in contributing to the pathogenesis of airway inflammatory diseases. Targeting these ion channels and aiming to modulate them may provide an interesting new approach to the therapy of these potentially fatal diseases.</p>
</sec>
<sec><h3>Methods</h3>
<p>We tested this hypothesis in both healthy and ovalbumin (OVA)-sensitized male Dunkin-Hartley guinea pigs. The ion channel activity was modulated by TMEM16A-nonselective (benzbromarone) and TMEM16A-selective blockers (CaCCinh-A01). <italic>In vivo</italic> airway reactivity, induced by histamine and methacholine, was expressed as specific airway resistance (sRaw) values. The number of citric acid-induced coughs was counted using a double-chambered body plethysmograph, and the frequency of ciliary beating (CBF) was assessed <italic>in vitro</italic> by brushing method. For comparison, salbutamol and codeine were tested under the same conditions.</p>
</sec>
<sec><h3>Results</h3>
<p>The results showed significant differences in the responses of unsensitized and sensitized airways to both TMEM16 blockers administered. CaCCinh-A01 and benzbromarone significantly reduced the number of cough efforts in the group of OVA-sensitized guinea pigs. Significant improvement in sRaw values could be observed in OVA-sensitized TMEM16 blocker–treated animals compared to salbutamol when challenged with inhalational histamine, and the outcome was similar to salbutamol when challenged with methacholine. CBF was significantly inhibited in animals sensitized to OVA treated with selective inhibition of TMEM16A.</p>
</sec>
<sec><h3>Conclusions</h3>
<p>The results demonstrated that treatment with blockers of TMEM16 can reduce both cough effort and sRaw, and the difference between TMEM16A-selective and TMEM16A-nonselective blocking is only negligibly in favor of CaCCinh-A01. It is also worthwhile to note the impairment of CBF in OVA-sensitized animals treated with CaCCinh-A01.</p>
</sec>
</abstract>

Comenius University in Bratislava Jessenius Faculty of Medicine in Martin: Univerzita Komenskeho v Bratislave Jesseniova Lekarska Fakulta v Martine

Biomedical Center (Biomed Martin), Jessenius School of Medicine

Experimental evaluation of the nonselective and selective TMEM16 family calcium-activated chloride channel blockers in the airways

<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec><h3>Background</h3>
<p>Mints (<italic>Mentha</italic> L., Lamiaceae) are medicinal plants frequently used in pharmacy, cosmetics, and food industry. Among the secondary metabolites found in mint, rosmarinic acid is one of the most abundant in the whole plant. Rosmarinic acid is known as a powerful antioxidant and anti-inflammatory agent.</p>
</sec>
<sec><h3>Aim</h3>
<p>There is much information about the use and profile of secondary metabolites of mint's aerial parts. On the contrary, less is known about the secondary metabolites in the rhizomes. So, this research intended to determine the content of rosmarinic acid in the underground parts of 10 species of the genus <italic>Mentha</italic>, section <italic>Mentha</italic>.</p>
</sec>
<sec><h3>Method</h3>
<p>High-performance liquid chromatography with diode array detection (HPLC-DAD) was used to identify and determine rosmarinic acid.</p>
</sec>
<sec><h3>Results</h3>
<p>Rosmarinic acid was detected in all 10 species. The highest amount was found in <italic>Mentha × piperita</italic> L. “BULHARSKA 1” and <italic>Mentha rotundifolia</italic> (L.) Huds. The lowest content of rosmarinic acid was found in <italic>Mentha arvensis</italic> L., and a slightly higher content was measured in <italic>Mentha × piperita</italic> L.</p>
</sec>
<sec><h3>Conclusion</h3>
<p>The underground parts of mints seem to be an interesting source of natural antioxidants such as rosmarinic acid.</p>
</sec>
</abstract>

Department of Pharmacognosy and Botany, Faculty of Pharmacy

Department of Cellular and Molecular Biology of Drugs, Faculty of Pharmacy

Rosmarinic Acid in Underground Parts of Different <italic>Mentha</italic> Species

<abstract xmlns="http://www.w3.org/1999/xhtml">

<p>The pseudo-fruits of Dog Rose are a rich source of L-ascorbic acid and several other active substances, which means their high supportive therapeutic potential. The study aimed to examine the impact of the chosen technological procedure for the preparation of tablets containing rosehip powder on the amount of L-ascorbic acid in the final pharmaceutical form. Drying of the plant drug was performed at room temperature to avoid possible thermal degradation of this heat-sensitive compound. Similarly, drying of the granules after wet granulation in the oven was replaced by natural drying at room temperature. The composition of two types of prepared granule formulations differed in the filler – lactose (LAC) or microcrystalline cellulose (MCC). Apart from the disintegration test, they meet the technological requirements for granules or tablets. Lactose was confirmed as a more suitable filler, which despite the unsuccessful disintegration of the granules, ensures the disintegration of tablets within 15 minutes even without the addition of a special excipient acting as a disintegrant. The content of L-ascorbic acid detected using isotachophoresis – capillary zone electrophoresis was 87.16 ± 5.06 µg in LAC tablets and 63.33 ± 2.83 µg in MCC tablets.</p>
</abstract>

Faculty of Pharmacy, Department of Galenic Pharmacy

Faculty of Pharmacy, Department of Pharmaceutical Analysis and Nuclear Pharmacy

Technological Processing of Dried Powdered Rosehips to Tablets Through Wet Granulation

<abstract xmlns="http://www.w3.org/1999/xhtml">

<sec><h3>Objective</h3>
<p>Due to the severe side effects of long-term treatment using hormone replacement therapy, Raloxifene (RLX) is introduced with beneficial effects on rheumatoid arthritis (RA) for postmenopausal women. This review was conducted to collect data from the available literature on RLX for the management of postmenopausal women suffering from RA.</p>
</sec>
<sec><h3>Method</h3>
<p>All studies published up to 2019 were searched in four databases, including Google Scholar, PubMed, Scopus, and Medline. All articles were searched using several keywords, including “Raloxifene” or “Evista” in combination with “Rheumatoid Arthritis” or “Autoimmunity”. Finally, six studies were selected for the review analysis of this study. In all studies, 60 mg/day RLX was administered for postmenopausal subjects. The majority of the studies showed that the use of RLX was effective in postmenopausal women who underwent corticosteroid therapy. No severe complications were reported after RLX therapy in patients with RA.</p>
</sec>
<sec><h3>Result</h3>
<p>Based on the obtained results, RLX is a selective estrogen receptor modulator that its short-term anti-arthritic effects are proven in the treatment of postmenopausal osteoporosis. It was well tolerated without serious adverse events.</p>
</sec>
<sec><h3>Conclusion</h3>
<p>It seems that RLX is a promising treatment candidate in postmenopausal RA due to its anti-arthritic and anti-osteoporotic effects and based on the outcomes of experimental postmenopausal arthritis in animal and human studies.</p>
</sec>
</abstract>

Role of raloxifene in the management of postmenopausal osteoporosis of rheumatoid arthritis patients

AHEAD OF PRINT

Volume 70 (2023): Issue 1 (December 2023)

Volume 70 (2023): Issue s1 (December 2023)

Volume 70 (2023): Issue 2 (December 2023)

Volume 69 (2022): Issue 2 (August 2022)

Volume 69 (2022): Issue s1 (July 2022)

Volume 69 (2022): Issue 1 (January 2022)

Volume 68 (2021): Issue 2 (December 2021)

Volume 68 (2021): Issue 1 (January 2021)

Volume 67 (2020): Issue 2 (May 2020)

Volume 67 (2020): Issue 1 (January 2020)

Volume 66 (2019): Issue 2 (November 2019)

Volume 66 (2019): Issue 1 (June 2019)

Volume 65 (2018): Issue 2 (November 2018)

Volume 65 (2018): Issue 1 (June 2018)

Volume 64 (2017): Issue 2 (November 2017)

Volume 64 (2017): Issue 1 (September 2017)

Volume 63 (2016): Issue s12 (December 2016)

Volume 63 (2016): Issue 2 (December 2016)

Volume 63 (2016): Issue 1 (September 2016)

Volume 62 (2015): Issue 2 (December 2015)

Volume 62 (2015): Issue 1 (June 2015)

Volume 62 (2015): Issue s10 (September 2015)

Volume 62 (2015): Issue s9 (June 2015)

Volume 61 (2014): Issue 2 (December 2014)

Volume 61 (2014): Issue 1 (August 2014)

Volume 60 (2013): Issue Supplementum-VIII (March 2013)<br/>Rare disease day in Slovakia, Europlan national conference

Volume 60 (2013): Issue 2 (December 2013)

Volume 60 (2013): Issue 1 (June 2013)

Volume 59 (2012): Issue 2 (November 2012)

Volume 59 (2012): Issue 1 (June 2012)

Volume 59 (2012): Issue Supplement-VII (February 2012)<br/>Conference abstracts, Rare disease day, conference 29.2.2012, First Slovak conference about rare diseases

Volume 59 (2012): Issue Supplement-VI (January 2012)<br/>Clinical Pharmacy in the Slovak Republic, dedicated to the associated professor Lívia Magulová, PhD.

Volume 58 (2011): Issue 1 (January 2011)

European Pharmaceutical Journal

  Formerly Acta Facultatis Pharmaceuticae Universitatis Comenianae.  All areas of pharmaceutical and related sciences.  Original research articles.    Why subscribe and read   To get informed on the research in pharmaceutical and related sciences mainly in the central Europe,  Articles written by young talented enthusiastic researchers,  To find new co operations.   Why submit   Official journal of Pharmaceutical Faculty, the oldest faculty of Pharmacy in former Czechoslovakia, keeping the tradition in pharmaceutical education in central Europe,  Fair and constructive review by the experts in the field,  Articles abstracted by online indexing services and databases.   Rejection Rate   50%   Archiving  Sciendo archives the contents of this journal in Portico - digital long-term preservation service of scholarly books, journals and collections.  Plagiarism Policy  The editorial board is participating in a growing community of Similarity Check System's users in order to ensure that the content published is original and trustworthy. Similarity Check is a medium that allows for comprehensive manuscripts screening, aimed to eliminate plagiarism and provide a high standard and quality peer-review process. 

European Pharmaceutical Journal

Volume 70 (2023): Issue 1 (December 2023)

Original Paper

Experimental evaluation of the nonselective and selective TMEM16 family calcium-activated chloride channel blockers in the airways

Rosmarinic Acid in Underground Parts of Different Mentha Species

Technological Processing of Dried Powdered Rosehips to Tablets Through Wet Granulation

Role of raloxifene in the management of postmenopausal osteoporosis of rheumatoid arthritis patients

Cerca

Tutti i volumi ed i numeri in questa rivista